There are very few published studies of agents having the potential to improve bone health in children with infl ammatory bowel disease (IBD). The objective of this study was to establish the effi cacy and safety of intranasal calcitonin in improving bone mineral density (BMD) in young patients with IBD and to defi ne additional factors that impact bone mineral accrual.
INTRODUCTION
Many studies to date have shown that bone mineralization is compromised in pediatric patients with infl ammatory bowel disease (IBD) in comparison to healthy peers ( 1 -4 ) . In addition, bone geometry and strength are altered in these children ( 5 ) . Although an increased fracture rate has not been confi rmed in pediatric patients with IBD ( 6 ), bone mineral accrual rate was found to be lower than that of healthy controls ( 4, 5 ) . Th e only interventional study to target bone health in children with IBD to date found no signifi cant eff ect of vitamin D on spinal bone mineral density (BMD) using doses equivalent to 1,700 IU daily with calcium supplementation for 6 months. However, the investigators did not evaluate the correlation between serum 25 hydroxy-vitamin D concentration (25OHD) and either vitamin D intake or BMD ( 7 ) .
Calcitonin is a naturally occurring antiresorptive hormone ( 8 ) . Salmon calcitonin is ~ 40 -50 times more potent than that derived from humans and is available as a nasal spray. Calcitonin has been shown to reduce spinal fracture risk and improve vertebral BMD in postmenopausal women with osteoporosis ( 9 ) . Th is agent also preserves vertebral bone mass when administered to patients receiving glucocorticoids ( 10 ) . Th e superior tolerability and ease of administration of calcitonin renders it attractive for use in pediatric populations ( 9 ) . Calcitonin was found to be more effi cacious than placebo in increasing BMD in children aft er renal transplantation ( 11 ) , it improved bone pain and radiologic signs of osteoporosis in young patients with thalassemia, ( 12 ) , and reduced bone resorption and pain in children with juvenile rheumatoid arthritis ( 13 ) . Many adult studies have provided both safety and effi cacy data for calcitonin. A recent review summarized the harms associated with intranasal calcitonin in this population as minor -local irritating eff ects of the upper respiratory tract; more signifi cant adverse events such as nausea and allergic reactions were noted mostly with the injectable form ( 9 ) . Th e few studies examining effi cacy of intranasal calcitonin in improving BMD in children, documented no signifi cant harm. Specifi cally, El-Husseini et al. ( 14 ) reported only " transient hypocalcemia " with a daily dose of 200 IU of calcitonin administered intranasally for 12 months, while Canatan et al. ( 12 ) administered 100 IU of calcitonin intranasally three times per week with no signifi cant adverse events noted. However, adverse events were not detailed.
Th e present study was an 18-month randomized, placebo-controlled, double-blind trial of the effi cacy and potential harms of intranasally administered calcitonin on total body and lumbar spine BMD of children with IBD. We evaluated these sites as representative of cortical bone (with slow skeletal turnover) and trabecular bone (with rapid turnover), respectively. In their recent position statements, the International Society for Clinical Densitometry endorsed these skeletal sites as important in the monitoring of children at risk for compromised bone health ( 15 ) . We did not examine the eff ect of calcitonin on the femoral neck. Although important in adults due to the established relationship between low BMD and fractures at this site, the femoral neck is less important in children. Th e hip is not a reliable site for measurement in growing children due to variability in skeletal development and lack of reproducible regions of interest. Th is leads to errors in positioning, lower precision measurements, and potential for systematic errors in clinical trials ( 15 ) .
To isolate the eff ect of calcitonin on bone mineral accrual rate, we collected prospective data on other contributing factors. While the positive eff ects of linear growth, lean mass growth, and pubertal development on bone mineral accrual rate have been confi rmed in both healthy children ( 16, 17 ) and children with IBD ( 5, 18, 19 ) , there have been contradictory reports on the role of glucocorticoids ( 4, 20, 21 ) and infl ammation ( 4, 21 ) on bone health in this population. In addition, the impact of weight-bearing activity and nutrition has not been examined in a prospective manner in children with IBD.
METHODS

Participants
Children, adolescents, and young adults with IBD, age 8 -22 years, receiving care at Children ' s Hospital Boston, underwent a screening dual energy X-ray absorptiometry (DXA) measurement of their lumbar spine as part of the screening phase of this study. Th e study was approved by the Institutional Review Board of the hospital, and all participants and their parents/guardians signed assent and informed consent respectively, prior to screening. Specifi cally, all participants and their families were given a description of the trial, as well as the potential benefi ts, risks, and discomforts associated with study participation by the investigators. Th e above were repeated for all young participants in age-appropriate language. All participants were asked to give a description of the trial and the risks and discomforts involved, to assure understanding of the trial and its risks, and they were asked again if they wished to participate. Participants younger than 18 years were then asked to sign an assent form, in addition to their parents / guardians. Young participants who expressed concerns or disagreement with enrollment, regardless of age, were not enrolled. Participants older than 18 years gave informed consent themselves. Subjects were eligible to participate in the trial if their screening spinal BMD Z -score was ≤ − 1.0 s.d. Exclusion criteria included use of growth hormone, anabolic steroids, calcitonin, or bisphosphonates in the 6 months prior to enrollment, pregnancy, allergy to salmon, and the diagnosis of renal failure, anorexia nervosa, thyroid disorders, and polycystic ovary syndrome. None of the participants had used growth hormone, anabolic steroids, or bone active agents at any time prior to enrollment. Th e study took place in the Clinical and Translational Study Unit of the hospital and was registered at www.clinicaltrials.gov , NCT 00621257.
Protocol
Participants were randomized to receive 200 IU of salmon calcitonin by nasal spray (Miacalcin, Novartis, Basel, Switzerland) or placebo once daily, administered in alternating nostrils. Participants younger than 11 years received 800 mg of elemental calcium daily and those aged 11 years and older received 1,200 mg of elemental calcium daily divided into two doses (calcium carbonate salt, TUMS GlaxoSmithKline, Brentford, Middlesex, UK). All participants received 400 IU of vitamin D 2 per day (Nature ' s Bounty, Bohemia, NY). Th e duration of the trial was 18 months.
Outcomes
Th e primary outcome was the change in DXA-measured spinal and total body BMD Z -score from screening to 18 months. Secondary outcomes included change in Z -scores from screening to 9 months and change in Z -scores adjusted for bone age. Th e frequency of adverse events occurence was also an outcome recorded in this trial.
Sample size
Th e sample size was calculated based on the known eff ect of calcitonin on spinal BMD in other patient groups ( 22 ) . A target recruitment of ~ 30 participants per arm provided 80 % power to detect the eff ect size at a signifi cance level of ≥ 0.05. Because no systematic report of harms resulting from intranasal calcitonin in children was available, the trial was not powered specifi cally with respect to risk of harm.
Treatment assignment
Participants were enrolled by the investigators aft er informed consent and assent was obtained. Participants were randomized upon enrollment. Randomization was stratifi ed for pubertal stage and gender utilizing the permuted block method. Participants were considered prepubertal, pubertal, or postpubertal if the development of sexual charac teristics (evaluated via inspection and palpation) placed them in Tanner stages 1, 2 -4, or 5, respectively, at the time of enrollment. Th e random allocation sequence was generated by the Clinical Research Program of the hospital utilizing soft ware developed for this purpose (SciRAN) and was implemented through a spreadsheet provided only to the research pharmacists who assigned the participants to their groups. Study medications were provided to participants shortly aft er randomization at the enrollment visit.
Masking
Participants, investigators, and the interpreter of DXA results were unaware of treatment assignment, and the laboratory values specifi c to this. Th e Data and Safety Monitoring Board for the study monitored laboratory values and assured the success of the blinding until the study ' s conclusion.
Evaluations
Follow-up visits occurred every 3 months. Th ey consisted of administration of study-specifi c questionnaires, nutritional evaluations by a research nutritionist, physical examination (including pubertal staging, and anthropometric measurements), and collection of laboratory data. DXA measurements were obtained at screening, 9, months and 18 months, and wrist fi lms were obtained at enrollment and 18 months for bone age determination. As this was an intention to treat study, we asked all participants to return for their DXA scans regardless of missed visits, compliance with the study medication, or withdrawal -participant or investigator initiated. Loss to follow-up was defi ned as unavailability of all primary outcomes.
Nutritional evaluation
Th e subjects completed prospectively the Children ' s Hospital Boston Clinical Nutrition Service 3-day Food and Beverage Diary at the initial, 9 month, and fi nal study visit, and 1-day diet recall questionnaires at other visits. Responses were analyzed using the Food Processor SQL Nutrition Analysis Soft ware (Version 9.2, ESHA Research, Salem, OR), to provide the average daily intake for each nutrient of interest, specifi cally: protein, carbohydrates, fat, calcium, vitamin D, vitamin K, sodium, potassium, phosphorus, and magnesium.
Anthropometric measurements
Subjects ' weights and heights were measured at every study visit. Weight (Wt) was measured on a Scale-Tronix digital scale (ScaleTronix, White Plains, NY), calibrated weekly. Height (Ht) was measured on a Holtain stadiometer (Holtain, Crymych, Wales, UK), calibrated daily. Body mass index (BMI), weight Z -score, height Z -score, and BMI Z -score were calculated using the Epi Info Database and Statistics Soft ware for Public Health Professionals (Centers for Disease Control and Prevention, Atlanta, GA, 2004). For patients ≥ 20 years, Z -scores were calculated using an age of 20 years.
DXA
A DXA scanner was used to measure lean body mass (kg), fat mass (kg), total body areal BMD including the head (g / cm 2 ), as well as lumbar spine areal BMD (g / cm 2 ) at enrollment and at the 18-month study visit ( 15 ) . Lumbar spine measurements were based on the anteroposterior view of L1 -L4 using a Hologic Discovery A scanner with v12.4 soft ware. Th e scanner was calibrated daily, using a quality control anthropomorphic spine phantom, provided by the manufacturer. BMD Z -scores were derived using pediatric soft ware ( 23, 24 ) for subjects aged 4 -20 years, and NHANES soft ware for patients above age 20 ( 25 ) and were additionally adjusted for bone age. We calculated lean mass for height Z -score and percent fat mass for age Z -score using the least mean square algorithm (LMS) based on reference values provided by Hologic. Th ese reference values were derived from a nationally representative sample from the NHANES survey and were acquired using Hologic Discovery A DXA scanners with soft ware compatible with ours ( 26 ) . Data generated by DXA were interpreted by one endocrinologist (C.M.G.).
Bone age
A radiograph of the non-dominant wrist was obtained at enrollment and at the 18-month follow-up visit for each subject. A trained radiologist reviewed the wrist fi lms and assigned bone age utilizing the method of Greulich and Pyle ( 27 ) .
Clinical characteristics
Participants ' pubertal status was determined at enrollment and end of the trial. Th e Centers for Disease Control and Prevention Youth Risk Behavior Survey (available at http://www.cdc.gov/ yrbss , accessed in Fall 2002) includes questions related to use of alcohol and tobacco, which were administered to identify participants who had engaged in smoking or alcohol use either prior to enrollment or during the trial. Specifi c questionnaires were used to report weight-bearing activity, both lifetime (reported as the total number of hours) and during the study. Participants were asked about their participation in any sports or activities that are considered weight-bearing at each study visit and reported the number of weeks of participation, and number of hours per week for the interval since their last study visit. Th e hours were then totaled and reported as average weekly hours of activity. Activities such as swimming and cycling were excluded, as non-weight-bearing activities ( Supplementary Tables E and F online). For female subjects, the use of contraceptive agents and / or estrogen replacement therapy was identifi ed via confi dential questionnaires, and medical record review of all clinic notes. Family history of low bone density was considered positive if a family member met the diagnosis based on a DXA result, or if a family member had severe kyphosis, pathologic fracture, or signifi cant loss of height ( 28 ) .
Diagnosis of Crohn ' s disease (CD) and ulcerative colitis (UC) was assigned based on histologic, endoscopic, radiographic, and clinical criteria ( 29 ) . Disease activity was scored at each visit utilizing the Pediatric CD Activity Index (PCDAI) (for subjects ≤ 20 years old), ( 30 ) CD Activity Index (CDAI) (for subjects >20 years old) ( 31 ) , or the Kozarek score in cases of UC ( 32 ) . Th e Kozarek score was used to quantify disease activity in our study as the Pediatric UC Activity Index was not formulated and validated until aft er the study was completed ( 33 ) . Th e Kozarek score is derived from the following fi ve parameters: number of liquid stools per day, severity of rectal bleeding, general well-being, level of abdominal pain, and extra-intestinal manifestations. Th ere had been prior experience in our center in the use of this scoring system and in the classifi cation of disease severity depending on the score ( 34 ) . A participant was classifi ed as having (i) " moderate / severe disease " during the trial, if PCDAI was Ն 30 or CDAI Ն 220 or Kozarek > 6; (ii) " mild disease " if PCDAI Ն 10 and < 30 or CDAI Ն 150 and < 220, or Kozarek Ն 4 and Յ 6; and (iii) " inactive disease " if PCDAI < 10 or CDAI < 150 or Kozarek < 4 ( 31, 34 ) . Medical record review was utilized for participants with CD to identify upper gastrointestinal tract involvement on the basis of histologic evidence of granulomas, and the occurrence of complications -specifi cally fi stulae and strictures and to calculate the cumulative systemic glucocorticoid dose in prednisone equivalents in all participants. Disease duration was reported in months from the fi rst histologic diagnosis to date of enrollment. Patient questionnaires and medical record review were used to report the use of nutritional supplements and enteral nutrition, occurrence of extra-intestinal manifestations, co-morbidities, operative procedures and hospitalizations related to IBD, and the use of immunomodulators and biologic agents. For the latter, we recorded length of treatment in months for each agent from diagnosis to enrollment, whether the participants were being treated with these agents at the time of enrollment, and the length of such treatment during the trial in months.
Laboratory values
Hematocrit ( % ), white blood cells (Kcells / μ l), and platelets (PLTs) (Kcells / μ l) were measured in an automated analyzer, either Advia -120 or Advia -2120 (Bayer Diagnostics, Tarrytown, PA), and erythrocyte sedimentation rate (ESR, mm / h) was measured using ESR analyzer Vesmatic 20 (HiChem Diagnostics Inc., Brea, CA), according to standard protocol. Serum albumin (g / dl), iron (Fe) ( μ g / dl), C-reactive protein (CRP) (mg / dl), and calcium concentration (mg / dl) were measured in a Roche / Hitachi 917 chemistry analyzer (Roche, Basel, Switzerland) according to standard protocol. Serum 25OHD concentration (ng / ml) was measured using the Nichols Advantage chemiluminescence-based competitive protein-binding assay (Nichols Institute Diagnostics, San Clemente, CA). Intact PTH (parathyroid hormone) (pg / ml) was measured using the Nichols Advantage Intact PTH Assay, a two-site chemiluminescence immunoassay (Nichols Institute Diagnostics).
Adverse events
Adverse events known to be associated with intranasal calcitonin administration (calcitonin package insert, ( 35 ) ) were included in our data collection instruments. Potential adverse events included allergic reaction, nasal mucosal wound (excoriation and / or abrasion verifi ed by direct inspection of the nares by the principal investigators), infection of the nasal tissue (evidence of infection of the nares or the surrounding skin verifi ed by the principal investigators), rhinitis (reports of nasal congestion or discharge), irritating eff ects to the upper respiratory tract (sneezing, itching of the nares), facial fl ushing, back pain, epistaxis, nausea, hyperparathryroidism (serum PTH concentration > 65 pg / ml at any of the study visits), and hypocalcemia (serum calcium concentration < 8 mg / dl at any of the study visits). In addition, participants were encouraged to report any other adverse events during the trial. An adverse event was characterized as unexpected if its nature, severity, or frequency was unanticipated based on previous experience with the study medication, in this case based on literature. Th is defi nition is in compliance with the guidelines of the Children ' s Hospital Boston Committee for Clinical Investigation. Adverse event severity was graded by agreement of both investigators and participants as mild (transient, without significant eff ect on daily activities, requiring minor interventions for relief), moderate (requiring medical attention and/or prescription medication for relief, but not signifi cantly impacting daily activities), severe (requiring hospitalization, infl icting long-term damage), or life threatening. Adverse event relationship to the study medication was assigned by both investigators and participants throughout the trial using the following algorithm: non-related, possibly related (included in the list of possible adverse events, but could be also explained by non-related process active in the participant), probably related (included in the list of possible adverse events, and could not be explained by any other process), unknown (relationship cannot be confi rmed or excluded).
Adverse events were collected through questionnaires specifically designed for this purpose. Th ese questionnaires contained the list of anticipated adverse events (see above) and laboratory abnormalities (see above), as well as severity and relatedness scales for each event (see above). Upon interview, the participants were fi rst asked if they have any unpleasant events to report (volunteered) and then the investigators went through the standard list of events (elicited). Th e questionnaires were administered every 3 months (at each study visit) for the duration of the trial. Both investigators and participants were blinded to treatment assignment, even when
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between the two groups using the χ 2 test. Taking into account all participants, the frequency of withdrawal due to adverse events, and timing of withdrawal (expressed as the number of participants withdrawn at enrollment, 3, 6, and 9 months) was compared between the two arms. No participant withdrew aft er 9 months. With all participants as the denominator, the frequency of unexpected adverse events was also compared between the two arms. Taking into account all adverse events, their distribution between the two arms, timing of occurrence (reported as average number of months from enrollment to event occurrence) and frequency of occurrence in the fi rst month, the fi rst 6 months, and aft er 6 months, severity, relatedness to study drug, and average duration in days was also compared between the two arms. Th e risk of multiple adverse events in a single participant was compared between the two arms, using as the denominator all participants with events. Th e study medication doses received (as percent of ideal) by all participants in the trial was reported and compared between the two arms.
RESULTS
Participant fl ow diagram and study timeline ( Figure 1 )
Population and disease characteristics at enrollment . Participants in the two arms did not diff er with respect to demo graphics, pubertal stage, anthropometrics, disease characteristics, and treatment (including length of treatment with immunomodulators or biologics from diagnosis to enrollment and treatment with these agents at the time of enrollment), habits, and exercise patterns ( Table 1 ) . Th e two arms diff ered only in diagnosis (CD more prevalent in the calcitonin arm), serum 25OHD concentration (higher in the calcitonin arm), and family history of osteoporosis (more prevalent in the calcitonin arm). When participants with CD were considered separately, the calci tonin group had higher rates of family history of osteoporosis but no other diff erences (results not shown) ( Supplementary Table A ).
Population and disease characteristics from enrollment to end for all and for participants with CD
When participants with CD and UC were combined, the calcitonin group participants received on average larger daily amounts of vitamin K ( μ g / day) (406 ± 825 vs. 122 ± 330, P = 0.03) and calcium (mg / day) (1,175 ± 509 vs. 922 ± 479, P = 0.05), but had no other diff erences (results not shown) ( Supplementary Table B ) .
Among participants with CD, those in the placebo group showed higher gains in weight Z -score (0.48 ± 0.72 vs. 0.08 ± 0.57, P = 0.05), had higher rates of complications by the end of the trial (9(45 % ) vs. 5(18.5 % ), P = 0.05), and engaged in fewer hours of weekly weight-bearing activity (3.6 ± 2.3 vs. 5.4 ± 3.5, P = 0.05), but no other diff erences were noted (results not shown) ( Supplementary Table B ). Withdrawal and loss to follow-up rates were similar between the two groups. Loss to follow-up alone -defi ned as missing all primary outcomes -was similar (placebo: 3 (9.4 % ), calcitonin: 5 (16.1 % ), P = 0.47) (not shown) ( Supplementary Table B ) .
an adverse event resulted in voluntary withdrawal of a participant or mandatory withdrawal by the investigators. By protocol, the trial would be terminated before its conclusion if serious, unexpected, and likely-related-to-calcitonin adverse events occurred as decided by the study ' s Data and Safety Monitoring Board.
Adherence
Questionnaires were administered at each visit to document adherence to study medications, which was expressed as a percentage of ideal intake.
Statistical analysis
Th e data were analyzed using the " intention to treat " assumption. A two-sided P value ≤ 0.05 was accepted as the level of signi fi cance. Descriptive statistics for population and clinical characteristics at enrollment, including body composition and anthro pometric measurements at screening, were tabulated separately for the two study arms and compared. Patient and disease characteristics, changes in anthropometric measurements and body composition measurements, average laboratory values, average nutrient intakes, and measures of compliance with study medications from enrollment to 18 months were tabulated for the two arms and compared. Th e comparisons were made between the two arms for the whole sample and for participants with CD separately. As a Supplementary Analysis , we compared the same characteristics, values, and measurements between the two arms from enrollment to 9 months and from 9 to 18 months in all participants and in participants with CD. χ 2 Tests were used to compare nominal variables. Two sample t -tests, or the Mann -Whitney test, depending on the distribution of the variables, were used to compare continuous variables. Distribution of each continuous variable was examined for normality using the Shapiro -Wilk test.
BMD Z -scores at screening, 9 months, and 18 months and changes in these scores from screening to 9 months (secondary outcome) and from screening to 18 months (primary outcome) were compared between the two arms in all participants utilizing the t -test or Mann -Whitney test as appropriate. Subgroup analyses were undertaken as well; the eff ect of treatment on the above primary and secondary outcomes was examined in patients with CD and UC separately, within participants of each pubertal group, and within participants who took >70 % of the nasal spray doses (adherent).
Simple relationships between several variables and the change in total body and spinal BMD Z -score from screening to 18 months were evaluated for signifi cance using correlation coeffi cient tests for continuous variables, and mean tests or analysis of variance tests for dichotomous or nominal values in all participants and participants with CD and UC separately. Non-parametric tests including Spearman correlation analyses, Mann -Whitney test, and Kruskal -Wallis analysis of variance were used when the data were not normally distributed based on the Shapiro -Wilk test. Because of the relatively small number of participants in this trial, we selected to report only unadjusted analysis results.
Th e cumulative and individual frequency of the occurrence of all adverse events related to the study medication was compared Excluded from analysis (n = 3) No primary outcome available Lost to follow-up/no primary outcome available (n = 3) 1 subject: unwilling to continue nasal spray and did not return 1 subject: moved 1 subject: no reason given Discontinued intervention (n = 7) * 2 subjects: adverse event 4 subjects: unwilling to continue nasal spray 1 subject: lost to follow-up and no access to study medications Allocated to placebo (n = 32) Received allocated intervention (n = 32)
Lost to follow-up/no primary outcome available (n = 5) 1 subject: adverse event and did not return 1 subject: unable to commute 3 subjects: no reason given Discontinued intervention (n = 7) * 3 subjects: adverse event 1 subject: withdrawn by investigator due to adverse event 1 subject: unwilling to continue nasal spray 2 subjects: lost to follow up and no access to study medications Table C ).
Population and disease characteristics from 9 to 18 months
We similarly examined the diff erences between these characteristics in the last part of the study ( Supplementary Table D ) . Of particular interest is the fall in adherence to the nasal spray administration during this study interval in comparison with the prior interval. Specifi cally, for all participants assigned to the calcitonin arm, the percent ideal doses of nasal spray received during the fi rst 9 months of the study was 73 % , vs. 57.6 % during the last 9 months.
For participants with CD assigned to the calcitonin group, the respective percent ideal nasal spray doses received was 70.2 % vs. 53.6 % . Adherence to the nasal spray followed the same trend in the placebo group and did not diff er from that of the calcitonin group.
Primary and secondary outcome analysis
BMD Z -scores and their changes in all participants . Total body and spinal BMD Z -scores at screening, 9 months, and 18 months and their changes from screening to 9 months and 18 months were compared between participants in the two arms and did not diff er ( Table 2 ). Of note is that total body BMD Z -score in either arm did not improve, and spinal BMD Z -score improved but did not normalize by the end of the study.
Subgroup analysis
Participants with CD and UC . Th e same analyses as above ( Table 2 ) were performed for participants with CD and UC separately ( Table 3 ). BA, adjusted for bone age; ZSBMD, spine bone mineral density Z -score; ZTBBMD, total body BMD Z -score; Δ ZTBBMD, change in total body BMD Z -score from screening to 9 or 18 months; Δ ZTBBMD, change in spine BMD Z -score from screening to 9 or 18 months. Italicized are primary outcomes.
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Other subgroup analysis . Comparisons of changes in total body and spinal BMD Z -score between the two therapeutic arms at 9 months and 18 months were also performed separately within each pubertal group. No signifi cant diff erences were noted between the two arms within the prepubertal (Tanner 1) or the pubertal group (Tanner 2, 3, 4); the postpubertal group contained too few participants with outcomes present for a meaningful comparison ( n = 9). Additionally, we compared primary and secondary outcomes in participants who took > 70 % ideal nasal spray doses (adherent only). Th ere were no signifi cant diff erences in any of the above outcomes between the two arms, except for the change in spinal BMD Z -score from 0 to 9 months in " adherent " patients with CD, which was positive in the calcitonin and negative in the placebo arm ( Δ ZSBMD calcitonin : 0.25 (0.35), Δ ZSBMD placebo : − 0.05 (0.41), P = 0.05).
Interestingly, among participants with CD, the calcitonin group showed a positive change in spinal BMD Z -score at 9 months, which was signifi cantly diff erent when compared with the negative change experienced by the participants in the placebo group. However, this advantage of the calcitonin group at 9 months did not persist to the end of the study, since the overall change in spinal BMD Z -score from screening to 18 months did not diff er in the two arms. Of note is that again, total body BMD Z -score of either arm did not improve, and spinal BMD Z -score improved, but did not normalize by the end of the study in participants with CD.
Th e outcomes did not diff er between the two arms in participants with UC. BMD Z -scores of participants with UC were higher than BMD Z -scores of participants with CD at baseline, 9, and 18 months. BA, adjusted for bone age; CD, Crohn's disease; UC, ulcerative colitis; ZSBMD, spine bone mineral density Z -score; Δ ZSBMD, change in spine BMD Z -score (from screening to 9 or 18 months); ZTBBMD, total body BMD Z -score; Δ ZTBBMD, change in total body BMD Z -score (from screening to 9 or 18 months).
Bolded values represent statistically signifi cant result.
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Variables affecting change in the total body and spinal BMD Z -score
Th e eff ect of several variables on total body and spinal BMD Z -score change from screening to 18 months was examined via simple relationship testing as described in the Methods section for all participants and for participants with CD and UC separately. Only signifi cant relationships are presented in the tables ( Tables 4 and 5 ).
Factors aff ecting change in total body BMD Z -score in all participants . Lower baseline total body BMD Z -score, increase in height Z -score, higher average serum iron concentration, hematocrit, serum albumin level, and more hours of weight-bearing activity per week were associated with increase in total body BMD Z -score, whereas higher average ESR, CRP, PLT count, and 25OHD serum concentration, the use of immunomodulators, surgery, and more severe disease were negatively associated with total body BMD Zscore change. Average serum 25OHD concentration was negatively associated with bone mineral accrual. However, this relationship is confounded by the paradoxical positive relationship between average serum 25OHD and average ESR in this study ( r = 0.437, P = 0.001), which could be attributed to higher amount of vitamin D supplementation by their clinicians in participants with more severe disease. Adjusted for ESR, average serum 25OHD lost its eff ect size and signifi cance in relationship with change in total body BMD Z -score ( β unadj = − 0.015 ( − 0.029, 0.000), P = 0.05, β adj = − 0.004 ( − 0.019, 0.011), P = 0.58) ( Table 4 ) .
Factors aff ecting change in spinal BMD Z -score in all participants . Higher baseline BMI Z -score and increase in height Z -score were associated with increase in spinal BMD Z -score, whereas higher average PLT count and percent fat for age were negatively associated spinal BMD Z -score change ( Table 5 ).
Factors aff ecting change in total body BMD Z -score in participants with CD and UC . Lower baseline BMD Z -score, increase in height Z -score, higher average serum albumin concentration, and hematocrit were associated with increase in total body BMD Zscore in participants with CD. Higher average ESR, CRP, and PLT count, and IBD-related hospitalization, surgery, and more severe for 1 week, but restarted at the advice or our Data and Safety Monitoring Board and the participant was discharged and followed by the neurology service, without further seizures for the duration of the trial and 1 year thereaft er. Th e relationship of this event to the study medication is unknown. One participant in the placebo arm had serum calcium concentration < 8 mg / dl identifi ed at one of the study visits. Th e participant was asymptomatic and the participant ' s calcium concentration normalized and remained > 8 for the duration of the trial aft er the dose of calcium supplement was increased. Table 7 depicts the experience with the study medication. Th e only identifi ed diff erence between the two arms was the adverse event timing. Adverse events in the calcitonin arm tended to occur later in the trial than those in the placebo arm. No adverse event recurred in any participant.
DISCUSSION
To our knowledge, this is the fi rst double-blind, placebo-controlled trial testing the effi cacy and safety of intranasal calcitonin in improving BMD in children, adolescents, and young adults with IBD. Intranasal calcitonin was well tolerated, and appeared to off er a short-term advantage in bone mineral acquisition rate at the spine in young patients with CD, but this advantage was not sustained. In addition, we observed that children and young adults with IBD and low BMD had bone mineral accrual rate that did not lead to " normalization " of their BMD Z -score (mean close to 0) during the span of our trial (18 months). Data were collected on many clinical variables that aff ect bone mineral accrual rate including a few novel observations. Specifi cally, we observed that a lower total body BMD Z -score at baseline was associated with greater gains over time, and that weight-bearing activity improved, whereas higher daily caff eine intake hampered bone mineral accumulation rate. Previous controlled studies of the eff ect of calcitonin in children reported positive results, although one utilized BMD T -score as the primary outcome instead of the recommended BMD Z -score ( 11 ) , and the other was a small trial ( 36 ) . While existing studies disease were negatively associated with total body BMD Z -score change. Average serum iron concentration and PLT count were, respectively, positively and negatively associated with changes in total body BMD Z -scores in participants with UC ( Table 4 ) .
Factors aff ecting change in spinal BMD Z -score in participants with CD and UC . Higher baseline BMI Z -score, lower baseline BMD Z -score, increase in height Z -score, and higher average serum albumin concentration were positively associated with increase in spinal BMD Z -score, whereas higher average ESR, CRP, PLT count, and daily caff eine intake were negatively associated with spinal BMD Z -score changes in participants with CD. Higher average PLT count was negatively associated with spinal BMD Z -score change in participants with UC ( Table 5 ).
Adverse events
Th e frequency of occurrence of adverse events related to the study medication did not diff er between the two arms ( Tables 6 and 7 ) . Th e most frequently encountered clinical events were epistaxis, irritation of the upper respiratory tract, and rhinitis. Hyperparathyroidism was encountered with similar frequency between the two arms, and was likely due to suboptimal vitamin D status. One participant in the calcitonin arm had an allergic reaction consisting of hives and pruritus, which was deemed to be related to the study medication and was withdrawn from the study aft er 1.5 months of participation (at the advice of the Data and Safety Monitoring Board). Th e participant received a short course (5 days) of oral prednisone and an antihistamine. Th e reaction resolved shortly thereaft er. Another participant in the calcitonin arm had an unexpected event: a complex partial seizure, while hospitalized for an IBD fl are. Th e hypothetical mechanism with which calcitonin could cause the occurrence of a seizure is through hypocalcemia secondary to disruption of bone resorption by osteoclasts, and consequently decrease in calcium release from bone to the circulation. Th e participant ' s serum calcium concentration was within normal limits. Th e study medication was temporarily discontinued BMD, bone mineral density; CD, Crohn's disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PLT, platelets; R , correlation coeffi cient; ZSBMD, spine BMD Z -score; ZBMI, body mass index Z -score; Δ ZHt, change in height Z -score; Δ Z % fat (age), change in percent fat adjusted for age Z -score; UC, ulcerative colitis.
PEDIATRICS
concur that bone formation rate is decreased in children with IBD ( 4,37 ), one study found decreased bone resorption rate at diagnosis ( 4 ), and another reported increased bone resorption rate during the course of their disease ( 37 ). We did not focus on the eff ect of calcitonin on bone turnover, which is the subject of a subsequent project in our center. Our rationale for its use in this study was that it would decrease bone resorption rate while bone formation rate recovers or remains stable, allowing for " catch-up " bone mineral accumulation rate. Our fi nding that calcitonin therapy advanced bone mineral accumulation rate in the spine of young patients with CD over the fi rst 9 months of the study does not yet support an application in clinical practice since it was the result of an underpowered subgroup analysis. Moreover, this benefi t did not persist to the end of the trial. Clearly, larger trials are needed in this population to confi rm or discredit this observation. A metaanalysis of the use of calcitonin for the treatment of postmenopausal osteoporosis suggested that it is eff ective in increasing BMD primarily at the spine, which is a site representative of trabecular bone, and a benefi cial trend was noted at the hip -representative of cortical bone ( 22 ) . More recent studies have shown that calcitonin improves trabecular bone microarchitecture ( 38 ) and therefore, may protect against fragility fractures. A recent study in children with IBD showed that trabecular BMD is decreased in newly diagnosed patients and remains low, although it initially improves aft er anti-infl ammatory treatment ( 5 ) . Studies have also shown that microarchitectural bone defi cits, specifi cally cortical thinning, are present in newly diagnosed pediatric patients with IBD, likely due to slower bone turnover as a result of infl ammation ( 5, 39 ) . Th is cortical defect remained even aft er treatment. Th e use of calcitonin early in the course of IBD, especially during phases of transition from decreased to increased bone resorption rate, while bone formation rate has not yet recovered, could assist in restoring or protecting both bone mass and microarchitecture, especially that of trabecular bone. Our study did not examine functional outcomes such as bone strength and fracture risk. Further research is needed to examine the eff ects of calcitonin on bone mineral accumulation rate in children with IBD who have suppressed bone formation rate in combination with pathologically accelerated bone resorption rate. Additional study of the impact of calcitonin on bone strength and fracture risk will be required before its routine use can be endorsed in children with IBD. Moreover, trials of calcitonin in selected pediatric populations could be considered to examine whether this agent may be more eff ective in pubertal patients in whom bone turnover is naturally accelerated. In terms of the safety of intranasal calcitonin, we report that it was well tolerated. Our experience is similar to that in adults, Z -score in the participants of this trial. Th is fi nding is in agreement with the fi ndings of other longitudinal studies that reported that bone mineral acquisition rate is not compensating for defi cits of bone mineral and structure observed at diagnosis in children with IBD ( 5, 19 ) . In contrast with these studies, our study followed children with IBD and low BMD at any point in the course of their disease. Although the severity of their disease fl uctuated during the study, they did not universally transition from a high with mostly minor and reversible harms associated with its use in children. Th e occurrence of a seizure in one participant of the calcitonin arm cannot be attributed to the medication with certainty, especially since the participant ' s serum calcium and 25OHD concentration were normal. Larger trials are needed to disprove or establish any such relationship. A signifi cant fi nding was the absence of improvement in total body BMD Z -score and inadequate improvement in spinal BMD infl ammatory state to a quiescent state like the children in the studies mentioned above. In addition, our participants ' lean mass, weight, and BMI Z -scores were either normal, or close to normal, where signifi cant defi cits of these anthropometric measures that could aff ect bone mineral accrual rate were observed at diagnosis in the above studies. As such, our observation that low BMD Z -score does not seem to signifi cantly improve over time is even more worrisome, since it may herald a more solidifi ed suboptimal bone health state. Clearly, additional longitudinal large-scale studies are needed to investigate outcomes such as peak bone mass achievement, fracture risk, and bone quality by early adulthood in children with IBD and low BMD. Th is prospective trial contributes a few novel fi ndings. First, we established a positive eff ect of weight-bearing activity on total body bone mineral accrual rate in children with IBD. Th is fi nding is not surprising since, according to the mechanostat theory, muscle force in addition to muscle load drives bone mass and strength attainment ( 40 ) . Exercise is benefi cial for bone mass and strength accrual in healthy children with optimal results seen during early puberty ( 41 ) . Studies in other patient groups have shown the value of weight-bearing activity for bone health in children with cystic fi brosis ( 42 ) , and juvenile rheumatoid arthritis ( 43 ) . In adults with IBD, a low impact exercise program of increasing intensity resulted in signifi cant BMD gains in compliant subjects ( 44 ) . Second, we demonstrated that subjects with lower baseline total body BMD Z -score demon strated higher bone mineral accrual rate. Th is association has also been noted in trials of antiresorptive medications and estrogens in women with low BMD ( 45, 46 ) and it was attributed to higher bone turnover rate in those subjects with the lowest BMD ( 47, 48 ) . A similar compensatory mechanism could stimulate bone turnover in pediatric subjects with a very low BMD. We propose that the association between lower baseline BMD Z -scores and higher bone mineral accrual rate be taken into consideration when evaluating the eff ect of other factors or interventions on the rate of bone mineral accrual in children with IBD. Th ird, we found that higher average daily caff eine consumption from all dietary sources during the study was independently associated with lower spinal bone mineral acquisition rate in participants with CD. Th e majority of caff eine in the diet of American children originates in caff einated soft drinks. Other investigators have found a negative relationship between daily amount of soft drinks and bone density in cross-sectional studies of healthy children ( 49, 50 ) . Th e hypothesis is that soft drinks displace other nutrients from the diet that are of importance to bone health, namely milk (which is a calcium and vitamin D source), and protein. In addition, it is known that caff eine interferes with calcium intestinal absorption, primarily when calcium intake is inadequate ( 51 ) . In our study population, we confi rmed that there was a signifi cant inverse correlation between caff eine and calcium intake among participants with CD.
In examining additional factors associated with bone mineral accrual rate, we observed that greater gains in Ht were associated with signifi cantly greater bone mineral accrual rate at both total body and spine, as shown also by others in healthy children ( 16 ) .
A previous longitudinal study found that changes in Ht Z -score were not associated with changes in BMD Z -score ( 4 ), but the BMD Z -scores in this study were adjusted for height -age, which may have led to an underestimate of the raw eff ect of linear growth on bone mineral accumulation rate. Th e fact that increases in Ht Zscore are associated with higher bone mineral accrual rate points towards the important role of growth-related hormones in bone mineral accrual rate. Growth hormone has been tightly linked with bone mass gains in both healthy children and growth-defi cient children aft er treatment with this hormone ( 52 ) . We also found that higher baseline BMI Z -score was associated with higher spinal bone mineral accrual rate. Several investigators found a positive relationship between BMI and bone health in children with IBD in cross-sectional studies ( 4, 18, 20, 53 ) . We hypo thesize that the fact that higher baseline BMI Z -score -rather than increase in BMI Zscore during the study -was associated with bone mineral accrual rate improvement points towards a temporal relationship where good nutritional status is a prerequisite for and has to precede an improvement in bone health.
We found a consistent impact of the infl ammatory state and both disease course and severity during the trial, on bone mineral accrual rate in CD and UC participants. Several investigators have previously found a negative relationship between infl ammatory state and BMD in cross-sectional studies of pediatric patients with IBD ( 4, 5, 18, 21, 54 ) . Only a few studies examined the impact of infl ammation on BMD in a longitudinal manner in this population and their fi ndings are not in agreement with our data ( 4,5 ). While we found that markers of infl ammation (PLT count, ESR), indicators of infl ammation (e.g., serum Fe concentration, albumin), and disease severity (e.g., use of immunomodulators) were associated with decreased total body and / or spinal bone mineral accrual rate, they did not detect a relationship between infl ammatory state and bone mineral accrual rate. However, these investigators examined incident cases of IBD, whereas our study included both incident and prevalent cases. As expected, an initial high level of infl ammation universally improved in the course of these studies, whereas infl ammation markers fl uctuated during our study, depending on each participant ' s disease course, thus providing an independent variable to test. Noteworthy is also the fact that other investigators examined disease activity indices and not specifi c markers. A constellation of markers may more accurately represent infl ammatory state.
Finally, we did not fi nd that glucocorticoid administration during the study was associated with total body or spinal bone mineral accrual rate. Th e eff ects of glucocorticoids on BMD have been studied mostly through cross-sectional studies in children with IBD which provided confl icting results, with some observing a negative eff ect of lifetime glucocorticoid dose on BMD ( 18, 55 ) , and others not ( 20, 21 ) . A recent longitudinal study found that the quality of bone built may be negatively aff ected by high concomitant glucocorticoid intake ( 5 ). Clearly, additional prospective studies are needed to focus on the eff ects of glucocorticoids on bone archi tecture and strength and their connection to outcomes such as fractures in this population.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Prevalence of suboptimal bone mineral density is higher in children with infl ammatory bowel disease (IBD) than their healthy peers. 3 Bone mineral accrual rate may not be adequate to compensate for bone mineral defi cits.
3 Infl ammation hampers bone accrual.
WHAT IS NEW HERE
3 Intranasal calcitonin is well tolerated, but offers no longterm benefi ts for bone health.
3 Larger trials are needed to explore whether subpopulations of children with infl ammatory bowel disease (IBD) would benefi t from calcitonin.
3 Weight-bearing activity increases the bone mineral accrual rate in children with IBD and low bone density.
3 Caffeine intake is associated with lower bone mineral accrual rates.
3 Defi cits in bone density do not correct over 18 months.
Our study has several limitations that deserve discussion. First, we were limited by the relatively small number of participants who completed the trial, and by the lack of healthy controls. Th e small number of participants specifi cally precluded multivariable analysis. Second, the DXA measurement of total body BMD (and respective BMD Z -score) included the skull due to a soft ware limitation. Experts have suggested that such measurements ideally would not include the measurement of skull BMD ( 15 ) . However, since this was a randomized trial, we expect that the minimal contribution of the skull to total body bone mineral accrual rate would have been balanced between the two arms. Strengths of our trial include that it was designed and conducted according to the gold standard in clinical experimentation -the double-blind, placebocontrolled clinical trial and it is the fi rst systematic study of a therapeutic agent for the improvement of bone health in children with IBD. Moreover, because of its prospective design, it has provided valuable unbiased data on the eff ect of several factors on bone mineral accrual rate.
In conclusion, we found that calcitonin is well tolerated, but did not improve bone mineral accrual rate in young patients with IBD. A temporary advantage in bone mineral accrual rate in the subgroup of young patients with CD has to be confi rmed by larger studies. As well, further studies are needed to examine which pediatric IBD populations may benefi t from calcitonin therapy for bone health. As others before, we found that bone mineral accrual rate of children with low BMD Z -score and IBD do not increase in a manner that would allow for normalization of this score, at least in the 18 months of the study.
Factors benefiting bone mineral accrual rate were lower baseline BMD Z -score, linear growth, weight-bearing exercise, and better baseline nutritional status. Higher degree of inflammation and more severe disease, and higher consumption of caffeine were associated with lower bone mineral accrual rate. Further studies are needed to confirm these findings, so that therapeutic and preventive interventions can focus on improving the corresponding aspects of care of young patients with IBD, which are amenable to improvement, helping these patients maximize their potential for optimal bone health in their adult years.
